Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Offers Free Access Program for Zolgensma Diagnostic
May 11, 2020
- Jitsubo Licenses Peptide Manufacturing Technology to Bachem
May 11, 2020
- Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
- Chugai Begins Joint Research with Singapore Agency on Novel Antibody Drug for COVID-19
May 11, 2020
- 4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
May 11, 2020
- Astellas to Carry on Teleworking through End of May
May 11, 2020
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
- Daiichi Sankyo Seeks Gastric Cancer Use for Enhertu
May 8, 2020
- Sales Rep Promotions Decrease 34%, Seminars Down 84%: Intage
May 8, 2020
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
- Takeda to Maintain Partial Voluntary Ban on Sales Reps Activities in Japan amid Coronavirus Woes
May 8, 2020
- Kyowa Kirin’s Q1 Sales Tick Up as North America Revenue Counters Japan Dip
May 7, 2020
- Fujifilm to Carry Out Process Development, Manufacturing of COVID-19 Treatment for Anti-COVID-19 Initiative
May 7, 2020
- Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
- Sanofi Warns of QT Prolongation for Plaquenil after FDA/EMA Flag Risks in COVID-19
May 1, 2020
- Taisho Licenses HIF-PH Inhibitor to US Biotech for Age-Related Diseases
May 1, 2020
- Mitsubishi Tanabe Drops Seasonal Flu Vaccine Project in US, Canadian Plan Intact
April 30, 2020
- Wakamoto, Rohto Forge Comprehensive Biz Tie-Up
April 30, 2020
- Shionogi’s Novel Antibiotic Cefiderocol Approved in Europe
April 30, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…